References
1. Huret, B., et al., [Pyopneumothorax in rheumatoid
arthritis]. Rev Mal Respir, 2017.
2. Das, S. and P. Padhan, An Overview of the Extraarticular
Involvement in Rheumatoid Arthritis and its Management. J Pharmacol
Pharmacother, 2017. 8 (3): p. 81-86.
3. Mori, S., et al., Prevalence of and factors associated with
renal dysfunction in rheumatoid arthritis patients: a cross-sectional
study in community hospitals. Clin Rheumatol, 2017. 36 (12): p.
2673-2682.
4. Nagaraj, S., et al., Early Rheumatoid Arthritis Presentation,
Treatment and Outcomes in Aboriginal Patients in Canada: A Canadian
Early Arthritis Cohort Study Analysis. Arthritis Care Res (Hoboken),
2017.
5. Buttgereit, F., et al., Standardised nomenclature for
glucocorticoid dosages and glucocorticoid treatment regimens: current
questions and tentative answers in rheumatology. Ann Rheum Dis, 2002.61 (8): p. 718-22.
6. Chatzidionysiou, K., et al., Efficacy of glucocorticoids,
conventional and targeted synthetic disease-modifying antirheumatic
drugs: a systematic literature review informing the 2016 update of the
EULAR recommendations for the management of rheumatoid arthritis. 2017.76 (6): p. 1102-1107.
7. Sharif, K., et al., Physical activity and autoimmune diseases:
Get moving and manage the disease. Autoimmun Rev, 2017.
8. Scott, L.J., Tocilizumab: A Review in Rheumatoid Arthritis.Drugs, 2017. 77 (17): p. 1865-1879.
9. Singh, J.A., et al., Adverse effects of biologics: a network
meta-analysis and Cochrane overview. Cochrane Database Syst Rev,
2011(2): p. Cd008794.
10. Gaitonde, P., L.M. Bozzi, and F.T. Shaya, Factors associated
with use of disease modifying agents for rheumatoid arthritis in the
National Hospital and Ambulatory Medical Care Survey. Semin Arthritis
Rheum, 2017.
11. van Steenbergen, H.W., et al., Preventing progression from
arthralgia to arthritis: targeting the right patients. Nat Rev
Rheumatol, 2017.
12. Lin, T.C., et al., Comparative Risk of Cardiovascular Outcomes
Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With
Rheumatoid Arthritis. J Am Heart Assoc, 2017. 6 (11).
13. Turesson, C., Comorbidity in rheumatoid arthritis. Swiss Med
Wkly, 2016. 146 : p. w14290.
14. Santos, H., et al., Effectiveness of early adalimumab therapy
in psoriatic arthritis patients from Reuma.pt - EARLY PsA. Acta
Reumatol Port, 2017. 42 (4): p. 287-299.
15. Ceccarelli, F., et al., Remission in early, aggressive
rheumatoid arthritis: a multicentre prospective observational Italian
study ARPA (Artrite Reumatoide Precoce Aggressiva). Clin Exp Rheumatol,
2013. 31 (3): p. 341-9.
16. Burgers, L.E., K. Raza, and A.H. van der Helm-van Mil, Window
of opportunity in rheumatoid arthritis - definitions and supporting
evidence: from old to new perspectives. RMD Open, 2019. 5 (1):
p. e000870.
17. Coffey, C.M., et al., Evidence of Diagnostic and Treatment
Delay in Seronegative Rheumatoid Arthritis: Missing the Window of
Opportunity. Mayo Clin Proc, 2019. 94 (11): p. 2241-2248.
18. van Mulligen, E., et al., Gradual tapering TNF inhibitors
versus conventional synthetic DMARDs after achieving controlled disease
in patients with rheumatoid arthritis: first-year results of the
randomised controlled TARA study. Ann Rheum Dis, 2019. 78 (6):
p. 746-753.
19. Lee, Z.M., et al., Correlation of symptomatic enterovirus
infection and later risk of allergic diseases via a population-based
cohort study. Medicine (Baltimore), 2017. 96 (4): p. e5827.
20. Lathia, U., E.M. Ewara, and F. Nantel, Impact of adherence to
biological agents on health care resource utilization for patients over
the age of 65 years with rheumatoid arthritis. Patient Prefer
Adherence, 2017. 11 : p. 1133-1142.
21. Chin-Hung Chen, V., et al., Factors affecting lumbar surgery
outcome: A nation-wide, population-based retrospective study. J Affect
Disord, 2017. 222 : p. 98-102.
22. Pedersen, J.K., et al., Mortality and its predictors in
patients with rheumatoid arthritis: a Danish population-based inception
cohort study. Scand J Rheumatol, 2018: p. 1-7.
23. Chang, K., et al., Smoking and rheumatoid arthritis. Int J
Mol Sci, 2014. 15 (12): p. 22279-95.
24. Shafia, S., et al., Rheumatoid arthritis and genetic
variations in cytokine genes: a population-based study in Kashmir
Valley. Immunol Invest, 2014. 43 (4): p. 349-59.
25. Savage, E.M., et al., Does rheumatoid arthritis disease
activity correlate with weather conditions? Rheumatol Int, 2015.35 (5): p. 887-90.
26. Quinn, M.A. and P. Emery, Window of opportunity in early
rheumatoid arthritis: possibility of altering the disease process with
early intervention. Clin Exp Rheumatol, 2003. 21 (5 Suppl 31):
p. S154-7.
27. Contreras-Yanez, I. and V. Pascual-Ramos, Window of
opportunity to achieve major outcomes in early rheumatoid arthritis
patients: how persistence with therapy matters. Arthritis Res Ther,
2015. 17 : p. 177.
28. Ramiro, S., et al., Safety of synthetic and biological DMARDs:
a systematic literature review informing the 2013 update of the EULAR
recommendations for management of rheumatoid arthritis. Ann Rheum Dis,
2014. 73 (3): p. 529-35.
29. Hashimoto, M., et al., Factors associated with the achievement
of biological disease-modifying antirheumatic drug-free remission in
rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther,
2018. 20 (1): p. 165.
30. Grijalva, C.G., et al., Initiation of tumor necrosis
factor-alpha antagonists and the risk of hospitalization for infection
in patients with autoimmune diseases. JAMA, 2011. 306 (21): p.
2331-9.
31. Smolen, J.S., et al., EULAR recommendations for the management
of rheumatoid arthritis with synthetic and biological disease-modifying
antirheumatic drugs: 2016 update. Ann Rheum Dis, 2017. 76 (6):
p. 960-977.